Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 8Mycosis Fungoides 3Lymphoma, T-Cell, Peripheral 3Recurrence 2Lymphoma, T-Cell, Cutaneous 2Sezary Syndrome 1Mesothelioma, Malignant 1Lymphomatoid Papulosis 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Large Granular Lymphocytic 1

Interventions

Cyclophosphamide 20Rituximab 18obinutuzumab 14Lenalidomide 14zanubrutinib 11fludarabine 10Bendamustine Hydrochloride 10Prednisone 8Magnetic Resonance Spectroscopy 8Vincristine 7Doxorubicin 7Specimen Handling 6fludarabine phosphate 5Radiotherapy 4Biopsy 4axicabtagene ciloleucel 3Whole-Body Irradiation 3tisagenlecleucel 2polatuzumab vedotin 2pirtobrutinib 2loncastuximab tesirine 2Therapeutics 2Prednisolone 2Positron Emission Tomography Computed Tomography 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Leukapheresis 2Immunotherapy, Adoptive 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Follicular × Brentuximab Vedotin × Clear all
NCT04587687 2025-04-24

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

University of California, Davis

Phase 2 Recruiting
23 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡